Gradient bionic stent for guiding combined repair of soft and hard tissues of oral cavity
Through the design of gradient bionic scaffolds and electrospinning technology, the problem of uncontrollable degradation cycle of GBR barrier membrane in vivo and lack of osteogenic activity factors is solved, and the joint repair of oral soft and hard tissues is achieved, which significantly improves tissue regeneration efficiency and safety sex.
Patent Information
- Application Number
- CN202411042468.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-31
AI Technical Summary
The existing guided bone regeneration (GBR) barrier membranes have uncontrollable degradation cycles in vivo, lack osteogenic activity factors, insufficient antibacterial performance, and risk of inflammation, making it difficult to effectively guide the joint repair of oral soft and hard tissues.
A gradient bionic scaffold was designed, including a soft tissue layer, a barrier layer and a hard tissue layer from top to bottom. It was prepared by electrospinning technology. The soft tissue layer is a loose porous layer, the barrier layer is a dense layer, and the hard tissue layer is an inducible layer. Osteogenic differentiation re-active factor layer, pore size distribution gradients of each layer, using polymer materials such as polylactic acid and collagen, combined with active factors such as VEGF and BMP-2 to form nanofiber structures.
Good mechanical properties and biocompatibility are achieved, soft tissue regeneration and osteogenesis processes are promoted, the barrier layer prevents fibroblasts from invading, provides a stable microenvironment, and significantly improves tissue regeneration efficiency and safety.
Smart Images

Figure CN118986551A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of oral implant dentistry, and in particular relates to a gradient bionic scaffold for guiding the combined repair of oral soft and hard tissues. Background Art
[0002] Guided bone regeneration (GBR) is an important medical technology for solving bone tissue defects. It spatially isolates soft tissue from bone repair sites, prevents the invasion of connective tissue cells, ensures that the osteogenesis process is not disturbed, and has significant clinical significance for periodontal treatment and oral implants. Existing GBR barrier membranes still have many limitations: uncontrollable degradation cycle in vivo, lack of osteogenic active factors, lack of antibacterial properties and inflammatory risks. Therefore, there is an urgent need for a gradient bionic scaffold that can be used to guide the combined repair of oral soft and hard tissues. Summary of the invention
[0003] The present invention provides a gradient bionic scaffold, which comprises a soft tissue layer, a barrier layer and a hard tissue layer in order from top to bottom.
[0004] According to an embodiment of the present invention, in the gradient bionic scaffold, the pore size distribution of each layer is: soft tissue layer>hard tissue layer>barrier layer.
[0005] According to an embodiment of the present invention, the soft tissue layer is in a gradient distribution. According to an embodiment of the present invention, the soft tissue layer is a loose porous layer. According to an embodiment of the present invention, the pore size of the soft tissue layer gradually decreases from the outside to the inside, and is in a gradient distribution.
[0006] According to an embodiment of the present invention, the barrier layer is a dense layer. The barrier layer can prevent fibroblasts from invading the osteogenic layer. The barrier layer can act as a barrier to soft tissue and provide a stable microenvironment for bone regeneration.
[0007] According to an embodiment of the present invention, the pore size of the soft tissue layer of the gradient bionic scaffold is 0.4μm-2.2μm; preferably, the pore size of the soft tissue layer is 0.5μm-2.0μm; for example, 0.55μm, 0.59μm, 0.60μm, 0.63μm, 0.70μm, 0.80μm, 0.90μm, 1.00μm, 1.30μm, 1.50μm, 1.80μm, 2.00μm. According to an embodiment of the present invention, the soft tissue layer includes an outer soft tissue layer, a middle soft tissue layer, and an inner soft tissue layer. According to an embodiment of the present invention, the pore size distribution is: outer soft tissue layer> middle soft tissue layer> inner soft tissue layer. According to an embodiment of the present invention, the pore size of the outer layer of the soft tissue layer is 1.0 μm-2.2 μm; preferably, the pore size of the outer layer of the soft tissue layer is 1.2 μm-2.0 μm; for example, 1.20 μm, 1.30 μm, 1.40 μm, 1.50 μm, 1.60 μm, 1.70 μm, 1.80 μm, 1.90 μm, 2.00 μm. According to an embodiment of the present invention, the pore size of the middle layer of the soft tissue layer is 0.5 μm-1.0 μm; for example, 0.60 μm, 0.63 μm, 0.65 μm, 0.68 μm, 0.70 μm, 0.75 μm, 0.80 μm, 0.90 μm. According to an embodiment of the present invention, the pore size of the inner layer of the soft tissue layer is 0.4 μm-0.7 μm; for example, 0.45 μm, 0.50 μm, 0.55 μm, 0.60 μm, 0.63 μm, 0.65 μm, 0.70 μm.
[0008] According to an embodiment of the present invention, the pore size of the barrier layer is 0.3 μm-0.7 μm; for example, 0.4 μm, 0.45 μm, 0.50 μm, 0.52 μm, 0.55 μm, 0.60 μm.
[0009] According to an embodiment of the present invention, the pore size of the hard tissue layer is 0.3μm-0.8μm. According to an embodiment of the present invention, the hard tissue layer includes an outer layer of a hard tissue layer and an inner layer of a hard tissue layer. According to an embodiment of the present invention, the pore size distribution is: the outer layer of the hard tissue layer> the inner layer of the hard tissue layer. According to an embodiment of the present invention, the pore size of the outer layer of the hard tissue layer is 0.4μm-0.8μm, for example, 0.45μm, 0.50μm, 0.53μm, 0.54μm, 0.55μm, 0.60μm, 0.65μm, 0.70μm. According to an embodiment of the present invention, the pore size of the inner layer of the hard tissue layer is 0.3μm-0.7μm, for example, 0.35μm, 0.4μm, 0.45μm, 0.50μm, 0.53μm, 0.54μm, 0.55μm, 0.60μm, 0.65μm.
[0010] According to an embodiment of the present invention, the thickness of the soft tissue layer, the barrier layer, and the hard tissue layer is 5-50 μm.
[0011] According to an embodiment of the present invention, the surface structure of the gradient bionic scaffold includes a directional parallel shape, a disordered cross shape, a cross shape or a radial shape.
[0012] According to an embodiment of the present invention, the soft tissue layer contains an active factor that can induce fibroblast adhesion and regeneration; preferably any one of VEGF and PDGF. According to an embodiment of the present invention, the soft tissue layer adopts the polymer material-1; preferably, the polymer material-1 is selected from any two or more of collagen, gelatin, chitosan, silk protein, hyaluronic acid, polycaprolactone, polylactic acid, polyvinyl alcohol, and methylcellulose. According to an embodiment of the present invention, the polymer material-1 is selected from polylactic acid and collagen; preferably, the mass ratio of polylactic acid to collagen is 5-20:1, for example 8:1, 10:1, 13:1, 15:1.
[0013] According to an embodiment of the present invention, the barrier layer adopts the polymer material-2; preferably, the polymer material-2 is selected from any one, two or more of collagen, gelatin, chitosan, silk fibroin, hyaluronic acid, polycaprolactone, polylactic acid, polyvinyl alcohol, and methylcellulose. According to an embodiment of the present invention, the polymer material-2 is selected from polylactic acid.
[0014] According to an embodiment of the present invention, the hard tissue layer contains an active factor that can induce cell osteogenic differentiation and regeneration; preferably any one of BMP-2, BMP-5, and BMP-7. According to an embodiment of the present invention, the hard tissue layer also contains an active factor that can induce fibroblast adhesion and regeneration; preferably any one of VEGF and PDGF. According to an embodiment of the present invention, the hard tissue layer adopts the polymer material-3; preferably, the polymer material-3 is selected from any two or more of collagen, gelatin, chitosan, silk protein, hyaluronic acid, polycaprolactone, polylactic acid, polyvinyl alcohol, and methylcellulose. According to an embodiment of the present invention, the polymer material-3 is selected from polylactic acid and collagen; preferably, the mass ratio of polylactic acid to collagen is 5-20:1, for example 8:1, 10:1, 13:1, 15:1.
[0015] According to an embodiment of the present invention, the soft tissue layer, the barrier layer and the hard tissue layer are prepared by electrospinning.
[0016] The present invention also provides a method for preparing the above-mentioned gradient bionic scaffold, which comprises the following steps:
[0017] S1: preparing electrospinning solution for soft tissue layer, electrospinning solution for barrier layer and electrospinning solution for hard tissue layer;
[0018] S2: The spinning solution in step S1 is subjected to electrospinning layer by layer in the order of soft tissue layer, barrier layer and hard tissue layer to obtain the gradient bionic scaffold.
[0019] According to an embodiment of the present invention, the electrospinning parameters include: voltage of 12-40 kV, flow rate of 1-3 mL / h, and rotation speed of 200-2000 r / min. According to an embodiment of the present invention, the soft tissue layer and the hard tissue layer are coaxially electrospun.
[0020] According to the embodiment of the present invention, the specific operating parameters of the electrospinning of the soft tissue layer are: coaxial electrospinning is performed using a 20-gauge coaxial needle, the distance between the needle and the receiver is 20 cm, the spinning voltage is 20 kV, the spinning time is 1 h, and the drum speed is increased from 200 r / min to 2000 r / min;
[0021] Preferably, the shell advancement rate is 1 mL / h;
[0022] Preferably, the core layer advancement speed is 0.5 mL / h;
[0023] Preferably, the drum speed increases in steps of 200 r / min, 500 r / min, 1000 r / min, and 2000 r / min.
[0024] According to an embodiment of the present invention, the specific operating parameters of the barrier layer electrospinning are:
[0025] A No. 20 needle was used, the distance between the needle and the receiver was 20 cm, a drum wrapped with aluminum foil was used as the receiving electrode, the propulsion speed was 1 mL / h, the drum speed was 3000 r / min, the spinning voltage was 20 kV, and the spinning time was 1 h.
[0026] According to an embodiment of the present invention, the specific operating parameters of the electrospinning of the hard tissue layer are:
[0027] For coaxial electrospinning, a 20 / 15 coaxial needle was used, the distance between the needle and the receiver was 20 cm, the drum speed was 200 r / min, the spinning voltage was 20 kV, and the spinning time was 1 h;
[0028] Preferably, the shell advancement rate is 1 mL / h;
[0029] Preferably, the core layer advancing speed is 0.5 mL / h.
[0030] According to an embodiment of the present invention, during the electrospinning process, the temperature is controlled at 26±3° C. and the humidity is controlled at 35±5%.
[0031] According to an embodiment of the present invention, after the electrospinning is completed, the fiber membrane is peeled off from the aluminum foil and ventilated in a fume hood for 48 hours to remove the residual solvent, thereby obtaining a gradient bionic scaffold.
[0032] According to an embodiment of the present invention, the average diameter of the nanofibers of the formed gradient bionic scaffold is 5nm-80nm; for example, 10nm, 20nm, 30nm, 40nm, 50nm, 60nm, 70nm.
[0033] According to an embodiment of the present invention, the soft tissue layer is prepared by electrospinning a soft tissue layer electrospinning solution.
[0034] According to an embodiment of the present invention, the preparation process of the soft tissue layer electrospinning solution is as follows: polymer material-1 and surfactant-1 are dissolved in solvent-1, and then active factor-1 solution is added, and the soft tissue layer electrospinning solution is obtained after stirring evenly.
[0035] According to an embodiment of the present invention, the concentration of the polymer material-1 is 0.04g / mL to 1g / mL; preferably 0.05g / mL to 0.5g / mL; for example, 0.06g / mL, 0.08g / mL, 0.10g / mL, 0.15g / mL, 0.2g / mL, 0.25g / mL, 0.3g / mL, 0.35g / mL, 0.4g / mL, 0.45g / mL, 0.5g / mL.
[0036] According to an embodiment of the present invention, the concentration of surfactant-1 is 1 μg / mL-20 μg / mL, for example, 5 μg / mL, 6 μg / mL, 8 μg / mL, 9 μg / mL, 10 μg / mL, 13 μg / mL, 15 μg / mL.
[0037] According to an embodiment of the present invention, the surfactant-1 is selected from non-ionic surfactants, preferably Span, such as Span 80.
[0038] According to an embodiment of the present invention, the active factor-1 is an active factor that can induce fibroblast adhesion and regeneration; preferably any one of VEGF and PDGF. According to an embodiment of the present invention, the active factor-1 is VEGF. According to an embodiment of the present invention, the concentration of the active factor-1 is 25-1000ng / mL, preferably 50ng / mL-500ng / mL, for example 100ng / mL, 150ng / mL, 180ng / mL, 200ng / mL, 250ng / mL, 300ng / mL, 350ng / mL, 400ng / mL, 450ng / mL, 500ng / mL.
[0039] According to an embodiment of the present invention, the active factor-1 solution is a solution formed by dissolving the active factor in a bovine serum albumin-PBS solution (eg, 2% BSA-PBS).
[0040] According to an embodiment of the present invention, the solvent-1 is selected from one, two or more of hexafluoroisopropanol, cresol, chloroform, formic acid, N,N dimethylformamide, N,N dimethylacetamide, trifluoroacetic acid, acetone, tetrahydrofuran, dimethyl sulfoxide, trifluoroethanol, dichloromethane, saturated zinc chloride solution, saturated calcium chloride solution, ethanol, methanol, and acetic acid; preferably hexafluoroisopropanol.
[0041] According to an embodiment of the present invention, the barrier layer is prepared by electrospinning a barrier layer electrospinning solution.
[0042] According to an embodiment of the present invention, the preparation process of the barrier layer electrospinning solution is as follows: polymer material-2 is dissolved in solvent-2, and the barrier layer electrospinning solution is obtained after stirring evenly.
[0043] According to an embodiment of the present invention, the polymer material-2 is selected from any one, two or more of collagen, gelatin, chitosan, silk fibroin, hyaluronic acid, polycaprolactone, polylactic acid, polyvinyl alcohol, and methylcellulose. According to an embodiment of the present invention, the polymer material-2 is selected from polylactic acid.
[0044] According to an embodiment of the present invention, the concentration of polymer material-2 in the electrospinning solution is 0.04 g / mL to 1 g / mL; preferably 0.05 g / mL to 0.5 g / mL; for example, 0.06 g / mL, 0.08 g / mL, 0.10 g / mL, 0.15 g / mL, 0.2 g / mL, 0.25 g / mL, 0.3 g / mL, 0.35 g / mL, 0.4 g / mL, 0.45 g / mL, and 0.5 g / mL.
[0045] According to an embodiment of the present invention, the solvent-2 is selected from one, two or more of hexafluoroisopropanol, cresol, chloroform, formic acid, N,N dimethylformamide, N,N dimethylacetamide, trifluoroacetic acid, acetone, tetrahydrofuran, dimethyl sulfoxide, trifluoroethanol, dichloromethane, saturated zinc chloride solution, saturated calcium chloride solution, ethanol, methanol, and acetic acid; preferably hexafluoroisopropanol.
[0046] According to an embodiment of the present invention, the hard tissue layer electrospinning solution includes a core layer electrospinning solution and a shell layer electrospinning solution.
[0047] According to an embodiment of the present invention, the preparation process of the hard tissue layer core electrospinning solution is as follows: polymer material-3 and surfactant-2 are dissolved in solvent-3, and then active factor-2 solution is added, and the core electrospinning solution is obtained after stirring evenly.
[0048] According to an embodiment of the present invention, the polymer material-3 is selected from any two or more of collagen, gelatin, chitosan, silk fibroin, hyaluronic acid, polycaprolactone, polylactic acid, polyvinyl alcohol, and methylcellulose. According to an embodiment of the present invention, the polymer material-3 is selected from polylactic acid and collagen; preferably, the mass ratio of polylactic acid to collagen is 5-20:1, for example, 10:1.
[0049] According to an embodiment of the present invention, the concentration of the polymer material-3 is 0.04g / mL to 1g / mL; preferably 0.05g / mL to 0.5g / mL; for example, 0.06g / mL, 0.08g / mL, 0.10g / mL, 0.15g / mL, 0.2g / mL, 0.25g / mL, 0.3g / mL, 0.35g / mL, 0.4g / mL, 0.45g / mL, and 0.5g / mL.
[0050] According to an embodiment of the present invention, the concentration of Surfactant-2 is 1 μg / mL-20 μg / mL, for example 5 μg / mL, 6 μg / mL, 8 μg / mL, 9 μg / mL, 10 μg / mL, 13 μg / mL, 15 μg / mL.
[0051] According to an embodiment of the present invention, the surfactant-2 is selected from non-ionic surfactants, preferably Span, such as Span 80.
[0052] According to an embodiment of the present invention, the active factor-2 is an active factor that can induce cell osteogenic differentiation and regeneration, preferably any one of BMP-2, BMP-5, and BMP-7. According to an embodiment of the present invention, the active factor-2 is BMP-2.
[0053] According to an embodiment of the present invention, the concentration of the active factor-2 is 25-1000 ng / mL, preferably 50 ng / mL-500 ng / mL, for example 100 ng / mL, 150 ng / mL, 180 ng / mL, 200 ng / mL, 250 ng / mL, 300 ng / mL, 350 ng / mL, 400 ng / mL, 450 ng / mL, 500 ng / mL.
[0054] According to an embodiment of the present invention, the active factor-2 solution is a solution formed by dissolving the active factor in a bovine serum albumin-PBS solution (2% BSA-PBS). According to an embodiment of the present invention, the active factor-2 is loaded on hydroxyapatite; preferably, 1 microgram is loaded on 25 mg of hydroxyapatite.
[0055] According to an embodiment of the present invention, the solvent-3 is selected from one, two or more of hexafluoroisopropanol, cresol, chloroform, formic acid, N,N dimethylformamide, N,N dimethylacetamide, trifluoroacetic acid, acetone, tetrahydrofuran, dimethyl sulfoxide, trifluoroethanol, dichloromethane, saturated zinc chloride solution, saturated calcium chloride solution, ethanol, methanol, and acetic acid; preferably hexafluoroisopropanol.
[0056] According to an embodiment of the present invention, the preparation process of the hard tissue layer shell electrospinning solution is as follows:
[0057] The polymer material-4 and the surfactant-3 are dissolved in the solvent-4, and then the active factor-3 solution is added and stirred evenly to obtain the shell electrospinning solution.
[0058] According to an embodiment of the present invention, the polymer material-4 is selected from any two or more of collagen, gelatin, chitosan, silk fibroin, hyaluronic acid, polycaprolactone, polylactic acid, polyvinyl alcohol, and methylcellulose. According to an embodiment of the present invention, the polymer material-4 is selected from polylactic acid and collagen; preferably, the mass ratio of polylactic acid to collagen is 5-20:1, for example, 10:1.
[0059] According to an embodiment of the present invention, the concentration of the polymer material-4 is 0.04g / mL to 1g / mL; preferably 0.05g / mL to 0.5g / mL; for example, 0.06g / mL, 0.08g / mL, 0.10g / mL, 0.15g / mL, 0.2g / mL, 0.25g / mL, 0.3g / mL, 0.35g / mL, 0.4g / mL, 0.45g / mL, and 0.5g / mL.
[0060] According to an embodiment of the present invention, the concentration of surfactant-3 is 1 μg / mL-20 μg / mL, for example 5 μg / mL, 6 μg / mL, 8 μg / mL, 9 μg / mL, 10 μg / mL, 13 μg / mL, 15 μg / mL.
[0061] According to an embodiment of the present invention, the surfactant-3 is selected from non-ionic surfactants, preferably Span, such as Span 80.
[0062] According to an embodiment of the present invention, the active factor-3 is an active factor that can induce fibroblast adhesion and regeneration, preferably any one of VEGF and PDGF. According to an embodiment of the present invention, the active factor-3 is VEGF.
[0063] According to an embodiment of the present invention, the concentration of the active factor-3 is 25-1000 ng / mL, preferably 50 ng / mL-500 ng / mL, for example 100 ng / mL, 150 ng / mL, 180 ng / mL, 200 ng / mL, 250 ng / mL, 300 ng / mL, 350 ng / mL, 400 ng / mL, 450 ng / mL, 500 ng / mL.
[0064] According to an embodiment of the present invention, the active factor-3 solution is a solution formed by dissolving the active factor in a bovine serum albumin-PBS solution (eg, 2% BSA-PBS).
[0065] According to an embodiment of the present invention, the solvent-4 is selected from one, two or more of hexafluoroisopropanol, cresol, chloroform, formic acid, N,N dimethylformamide, N,N dimethylacetamide, trifluoroacetic acid, acetone, tetrahydrofuran, dimethyl sulfoxide, trifluoroethanol, dichloromethane, saturated zinc chloride solution, saturated calcium chloride solution, ethanol, methanol, and acetic acid; preferably hexafluoroisopropanol.
[0066] The present invention also provides a gradient bionic scaffold prepared by the above preparation method.
[0067] The present invention also provides the preparation method and application of the gradient bionic scaffold in oral tissue engineering.
[0068] Beneficial Effects
[0069] Based on the anatomical characteristics of oral periodontal alveolar bone tissue and the difference in regeneration speed of soft and hard tissues, the present invention provides a method for preparing a gradient bionic scaffold including a soft tissue layer, a barrier layer, and a hard tissue layer using coaxial electrospinning technology. The gradient bionic scaffold exhibits good mechanical properties and biocompatibility. Among them, the gradient-distributed soft tissue layer can induce the adhesion and regeneration of fibroblasts, the barrier layer at the interface can prevent fibroblasts from invading the osteoblastic layer, and the hard tissue layer can induce the differentiation and regeneration of osteoblasts. The gradient bionic scaffold prepared by the present invention can be used as an excellent guiding material for the combined repair of oral soft and hard tissues, and has broad application prospects in oral medicine.
[0070] Compared with the commonly used GBR membrane, the gradient bionic scaffold prepared by the present invention utilizes coaxial electrospinning technology and controls the spinning solution and spinning parameters. Its loose porous layer has a bionic nano-morphology and a sustained-release effect of active factors, which can significantly promote tissue regeneration; its barrier layer can act as a barrier to soft tissue and provide a stable microenvironment for bone regeneration. BRIEF DESCRIPTION OF THE DRAWINGS
[0071] Figure 1:Design of gradient bionic scaffold: Based on the anatomical characteristics of oral tissue and the different regeneration rates of soft and hard tissues, a gradient bionic scaffold is constructed.
[0072] Figure 2 : Gradient bionic scaffold: The pore size of the soft tissue layer gradually decreases from the outside to the inside, and the pore size of the barrier layer is the smallest; the pore size of the hard tissue layer is smaller than that of the soft tissue layer, but larger than that of the barrier layer.
[0073] Figure 3 : The pore size of each layer of the gradient biomimetic scaffold.
[0074] Figure 4 : After combining the soft tissue layer and the hard tissue layer, the mechanical strength is improved;
[0075] Figure 5 :Cell proliferation: Compared with the control group, the composite membrane had no obvious killing effect on cells and had good cell compatibility.
[0076] Figure 6 :Cell penetration: The soft tissue layer can induce fibroblast penetration, and the barrier layer can effectively prevent them from invading the hard tissue layer.
[0077] Figure 7 :Gradient biomimetic scaffolds can promote angiogenesis.
[0078] Figure 8 : Gradient biomimetic scaffolds can promote bone regeneration. DETAILED DESCRIPTION
[0079] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.
[0080] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.
[0081] PLA: polylactic acid, purchased from NatureWorks, USA.
[0082] COL: collagen, purchased from Platinum Biotechnology (Shanghai) Co., Ltd.
[0083] HFIP: Hexafluoroisopropanol, purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.
[0084] Span80: Span 80 was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.
[0085] VEGF: vascular endothelial growth factor, purchased from PEPROTECH.
[0086] BSA-PBS solution: bovine serum albumin-PBS solution, purchased from Beijing Gypsy Biotechnology Co., Ltd.
[0087] BMP-2: human bone morphogenetic protein-2, purchased from PEPROTECH.
[0088] Fibroblasts were purchased from Shanghai Cell Bank, Chinese Academy of Sciences.
[0089] Vascular endothelial cells were purchased from the Shanghai Cell Bank, Chinese Academy of Sciences.
[0090] Osteoblasts were purchased from Shanghai Cell Bank, Chinese Academy of Sciences.
[0091] Example 1
[0092] Preparation of soft tissue layer: weigh 0.5g PLA and 0.05g COL, add them to 5mL HFIP solution, then add 50μl Span80, stir magnetically until a uniform solution is formed, dissolve 1μg VEGF in 500μl 2% BSA-PBS solution, then add it to the above solution, stir on a magnetic stirrer for 2h to obtain the soft tissue layer electrospinning solution.
[0093] Preparation of barrier layer: 1 g PLA was added to 10 mL HFIP and magnetically stirred until the solution was clear, which was used as the spinning solution for the barrier layer.
[0094] Preparation of hard tissue layer: weigh 0.5g PLA and 0.05g COL, add them to 5mL HFIP solution, then add 50 microliters Span80, and stir magnetically until a uniform solution is formed. Disperse 25mg hydroxyapatite loaded with BMP-2 (1 microgram) in 500 microliters 2% BSA-PBS solution, then add it to the above solution, stir on a magnetic stirrer for 2h, and ultrasonicate for 20 minutes to obtain the core electrospinning solution of the hard tissue layer; weigh 0.5g PLA and 0.05g COL, add them to 5mL HFIP solution, then add 50 microliters Span80, and stir magnetically until a uniform solution is formed. Dissolve 1 microgram VEGF in 500 microliters 2% BSA-PBS solution, then add it to the above solution, stir on a magnetic stirrer for 2h to obtain the shell electrospinning solution of the hard tissue layer.
[0095] Preparation of gradient bionic scaffolds: The spinning solution is sucked by a 10 mL syringe, and then the syringe is placed on a propulsion pump; the spinning solutions of the different layers are electrospun layer by layer in the order of soft tissue layer, barrier layer, and hard tissue layer to obtain gradient bionic scaffolds (such as Figure 1-2 shown).
[0096] (1) For the soft tissue layer, a 20-gauge coaxial needle was used for coaxial electrospinning. The distance between the needle and the receiver was 20 cm. The shell layer propulsion speed was 1 mL / h, the core layer propulsion speed was 0.5 mL / h, the drum speed increased by 200, 500, 1000, and 2000 r / min (each speed was maintained for 15 min), the spinning voltage was 20 kV, and the spinning time was 1 h.
[0097] (2) For the barrier layer, a 20-gauge needle was used, the distance between the needle and the receiver was 20 cm, a drum wrapped with aluminum foil was used as the receiving electrode, the syringe propulsion speed was 1 mL / h, the drum speed was 3000 r / min, the spinning voltage was 20 kV, and the spinning time was 1 h;
[0098] (3) For the hard tissue layer, a 20 / 15 coaxial needle was used for coaxial electrospinning. The distance between the needle and the receiver was 20 cm. The shell layer propulsion speed was 1 mL / h, the core layer propulsion speed was 0.5 mL / h, the drum speed was 200 r / min, the spinning voltage was 20 kV, and the spinning time was 1 h.
[0099] During the spinning process, the temperature was controlled at 26±3°C and the humidity was 35±5%. After the spinning was completed, the fiber membrane was peeled off from the aluminum foil and ventilated in a fume hood for 48 hours to remove the residual solvent, thereby obtaining the final gradient bionic scaffold.
[0100] The pore sizes of each layer of the prepared gradient bionic scaffold were detected by scanning electron microscopy. Figure 3 As shown in the figure, the pore size of the soft tissue layer gradually decreases from the outside to the inside, and the pore size of the barrier layer (isolation layer) is the smallest; the pore size of the hard tissue layer is smaller than that of the soft tissue layer, but larger than that of the barrier layer.
[0101] Example 2
[0102] The mechanical strength of the gradient bionic scaffold (composite layer) prepared in Example 1 was compared with that of the soft tissue layer and the hard tissue layer. The specific experimental method is as follows:
[0103] 1. Load the soft tissue layer, hard tissue layer and composite scaffold into the universal mechanical tester respectively;
[0104] 2. Perform stress testing according to the machine's setting program until the bracket breaks;
[0105] 3. Record and analyze data.
[0106] The experimental results are as follows Figure 4 As shown. Figure 4 It can be seen that the mechanical strength (including tensile stress and tensile strain) of the gradient bionic scaffold (composite layer) prepared in the present application is significantly improved.
[0107] Example 3
[0108] The cell compatibility of the gradient biomimetic scaffold (composite layer) prepared in Example 1 was studied, and the experimental method was as follows:
[0109] 1. Inoculate fibroblasts into the soft tissue layer of the gradient biomimetic scaffold, culture at 37°C, and change the medium every 2 days;
[0110] 2. Live cell staining on days 1, 4, and 7 of culture;
[0111] 3. Observe the proliferation of fibroblasts using confocal microscopy.
[0112] The experimental results are as follows Figure 5 As shown. Figure 5 It can be seen that compared with the blank control group (culture medium without material), the gradient bionic scaffold (composite layer) prepared in the present application has no obvious killing effect on L929 (fibroblasts) and has good cell compatibility.
[0113] Example 4
[0114] Observe and detect the proliferation and penetration of fibroblasts on the gradient bionic scaffold. The specific experimental process is as follows:
[0115] 1. Inoculate fibroblasts into the soft tissue layer of the gradient biomimetic scaffold, culture at 37°C, and change the medium every 2 days;
[0116] 2. Live cell staining on days 1, 4, and 7 of culture;
[0117] 3. Observe the proliferation and infiltration of fibroblasts using confocal microscopy.
[0118] The results are as follows Figure 6 As shown: fibroblasts proliferate significantly and penetrate into the soft tissue layer of the gradient bionic scaffold, but do not penetrate into the hard tissue layer. The results show that by designing the gradient pore size of each layer, the present application allows fibroblasts to enter the soft tissue side of the scaffold, but cannot break through the barrier layer and invade the hard tissue layer.
[0119] Example 5
[0120] Observe and detect the network formation of vascular endothelial cells on the gradient bionic scaffold. The specific experimental process is as follows:
[0121] 1. Co-culture vascular endothelial cells with gradient biomimetic scaffolds (transwell), culture at 37°C, and change the medium every 2 days;
[0122] 2. Culture until the set time point and observe the network formation of endothelial cells.
[0123] The results are as follows Figure 7Shown: Gradient biomimetic scaffolds can promote vascular endothelial cells to form vascular networks.
[0124] Example 6
[0125] Observe and detect the regeneration of osteoblasts on the gradient bionic scaffold. The specific experimental process is as follows:
[0126] 1. Co-culture osteoblasts with gradient biomimetic scaffolds at 37°C and change the medium every 2 days;
[0127] 2. After culturing for the set time points of 7, 14, and 21 days, the cells were stained with alkaline phosphatase reagent and alizarin red staining solution, respectively, to observe the osteogenic properties.
[0128] The results are as follows Figure 8 Shown: Gradient biomimetic scaffolds can promote the alkaline phosphatase activity of osteoblasts and the formation of calcium crystals.
[0129] The above is an explanation of the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A gradient bionic scaffold, which comprises a soft tissue layer, a barrier layer, and a hard tissue layer from top to bottom; Preferably, in the gradient bionic scaffold, the pore size distribution of each layer is: soft tissue layer>hard tissue layer>barrier layer; Preferably, the soft tissue layer is in a gradient distribution; preferably, the soft tissue layer is a loose porous layer; preferably, the pore size of the soft tissue layer gradually decreases from the outside to the inside, in a gradient distribution; Preferably, the barrier layer is a dense layer; Preferably, the pore size of the soft tissue layer of the gradient bionic scaffold is 0.4 μm-2.2 μm; preferably, the pore size of the barrier layer is 0.3 μm-0.7 μm; preferably, the pore size of the hard tissue layer is 0.3 μm-0.8 μm; Preferably, the thickness of the soft tissue layer, the barrier layer, and the hard tissue layer is 5-50 μm; Preferably, the surface structure of the gradient bionic scaffold includes directional parallel shape, disordered cross shape, cross shape or radial shape.
2. The gradient bionic scaffold according to claim 1, characterized in that: The soft tissue layer contains active factors that can induce fibroblast adhesion and regeneration; Preferably, the soft tissue layer adopts the polymer material-1; preferably, the polymer material-1 is selected from any two or more of collagen, gelatin, chitosan, silk fibroin, hyaluronic acid, polycaprolactone, polylactic acid, polyvinyl alcohol, and methylcellulose; Preferably, the barrier layer adopts the polymer material-2; preferably, the polymer material-2 is selected from any one, two or more of collagen, gelatin, chitosan, silk fibroin, hyaluronic acid, polycaprolactone, polylactic acid, polyvinyl alcohol, and methyl cellulose; Preferably, the hard tissue layer contains active factors that can induce osteogenic differentiation and regeneration of cells; preferably, the hard tissue layer also contains active factors that can induce fibroblast adhesion and regeneration; Preferably, the hard tissue layer adopts the polymer material-3; preferably, the polymer material-3 is selected from any two or more of collagen, gelatin, chitosan, silk fibroin, hyaluronic acid, polycaprolactone, polylactic acid, polyvinyl alcohol, and methylcellulose; Preferably, the soft tissue layer, the barrier layer and the hard tissue layer are prepared by electrospinning.
3. A method for preparing the gradient biomimetic scaffold according to any one of claims 1 to 2, comprising the following steps: S1: preparing electrospinning solution for soft tissue layer, electrospinning solution for barrier layer and electrospinning solution for hard tissue layer; S2: The spinning solution in step S1 is subjected to electrospinning layer by layer in the order of soft tissue layer, barrier layer and hard tissue layer to obtain the gradient bionic scaffold.
4. The preparation method according to claim 3, characterized in that: The electrospinning parameters were set as follows: voltage 12-40 kV, flow rate 1-3 mL / h, and rotation speed 200-2000 r / min; Preferably, the soft tissue layer and the hard tissue layer are coaxially electrospun; Preferably, the specific operating parameters of the soft tissue layer electrospinning are: coaxial electrospinning with a 20-gauge coaxial needle, a distance of 20 cm between the needle and the receiver, a spinning voltage of 20 kV, a spinning time of 1 h, and a drum speed increasing from 200 r / min to 2000 r / min; preferably, the shell layer advancing speed is 1 mL / h; preferably, the core layer advancing speed is 0.5 mL / h; Preferably, the specific operating parameters of the barrier layer electrospinning are: a 20-gauge needle is used, the distance between the needle and the receiver is 20 cm, a drum wrapped with aluminum foil is used as the receiving electrode, the propulsion speed is 1 mL / h, the drum speed is 3000 r / min, the spinning voltage is 20 kV, and the spinning time is 1 h; Preferably, the specific operating parameters of the electrospinning of the hard tissue layer are: coaxial electrospinning, using a 20 / 15 coaxial needle, the distance between the needle and the receiver is 20 cm, the drum speed is 200 r / min, the spinning voltage is 20 kV, and the spinning time is 1 h; preferably, the shell layer advancing speed is 1 mL / h; preferably, the core layer advancing speed is 0.5 mL / h; Preferably, during the electrospinning process, the temperature is controlled at 26±3°C and the humidity is 35±5%; Preferably, after the electrospinning is completed, the fiber membrane is peeled off from the aluminum foil and ventilated in a fume hood for 48 hours to remove the residual solvent, thereby obtaining a gradient bionic scaffold; Preferably, the average diameter of the nanofibers of the formed gradient bionic scaffold is 5nm-80nm.
5. The preparation method according to claim 3 or 4, characterized in that: The soft tissue layer is prepared by electrospinning a soft tissue layer electrospinning solution; Preferably, the preparation process of the soft tissue layer electrospinning solution is as follows: dissolving the polymer material-1 and the surfactant-1 in the solvent-1, then adding the active factor-1 solution, and stirring evenly to obtain the soft tissue layer electrospinning solution; Preferably, the concentration of the polymer material-1 is 0.04 g / mL to 1 g / mL; Preferably, the concentration of the surfactant-1 is 1 μg / mL-20 μg / mL; Preferably, the surfactant-1 is selected from nonionic surfactants; Preferably, the active factor-1 is an active factor that can induce fibroblast adhesion and regeneration; Preferably, the concentration of the active factor-1 is 25-1000 ng / mL; Preferably, the solvent-1 is selected from one, two or more of hexafluoroisopropanol, cresol, chloroform, formic acid, N,N-dimethylformamide, N,N-dimethylacetamide, trifluoroacetic acid, acetone, tetrahydrofuran, dimethyl sulfoxide, trifluoroethanol, dichloromethane, saturated zinc chloride solution, saturated calcium chloride solution, ethanol, methanol and acetic acid.
6. The preparation method according to claim 3 or 4, characterized in that: The barrier layer is prepared by electrospinning a barrier layer electrospinning solution; Preferably, the preparation process of the barrier layer electrospinning solution is as follows: dissolving polymer material-2 in solvent-2, and stirring evenly to obtain the barrier layer electrospinning solution; Preferably, the polymer material-2 is selected from any one, two or more of collagen, gelatin, chitosan, silk fibroin, hyaluronic acid, polycaprolactone, polylactic acid, polyvinyl alcohol, and methylcellulose; Preferably, the concentration of polymer material-2 in the electrospinning solution is 0.04 g / mL to 1 g / mL; Preferably, the solvent-2 is selected from one, two or more of hexafluoroisopropanol, cresol, chloroform, formic acid, N,N-dimethylformamide, N,N-dimethylacetamide, trifluoroacetic acid, acetone, tetrahydrofuran, dimethyl sulfoxide, trifluoroethanol, dichloromethane, saturated zinc chloride solution, saturated calcium chloride solution, ethanol, methanol and acetic acid.
7. The preparation method according to claim 3 or 4, characterized in that: The hard tissue layer electrospinning solution includes a core layer electrospinning solution and a shell layer electrospinning solution; Preferably, the preparation process of the hard tissue layer core electrospinning solution is as follows: dissolving polymer material-3 and surfactant-2 in solvent-3, then adding active factor-2 solution, and stirring evenly to obtain the core electrospinning solution; Preferably, the polymer material-3 is selected from any two or more of collagen, gelatin, chitosan, silk fibroin, hyaluronic acid, polycaprolactone, polylactic acid, polyvinyl alcohol, and methylcellulose; Preferably, the concentration of the polymer material-3 is 0.04 g / mL to 1 g / mL; Preferably, the concentration of surfactant-2 is 1 μg / mL-20 μg / mL; Preferably, surfactant-2 is selected from nonionic surfactants; Preferably, the active factor-2 is an active factor that can induce osteogenic differentiation and regeneration of cells; Preferably, the concentration of active factor-2 is 25-1000 ng / mL; Preferably, the solvent-3 is selected from one, two or more of hexafluoroisopropanol, cresol, chloroform, formic acid, N,N-dimethylformamide, N,N-dimethylacetamide, trifluoroacetic acid, acetone, tetrahydrofuran, dimethyl sulfoxide, trifluoroethanol, dichloromethane, saturated zinc chloride solution, saturated calcium chloride solution, ethanol, methanol and acetic acid.
8. The preparation method according to claim 7, characterized in that: The preparation process of the hard tissue layer shell electrospinning solution is as follows: polymer material-4 and surfactant-3 are dissolved in solvent-4, and then active factor-3 solution is added, and the shell electrospinning solution is obtained after stirring evenly; Preferably, the polymer material-4 is selected from any two or more of collagen, gelatin, chitosan, silk fibroin, hyaluronic acid, polycaprolactone, polylactic acid, polyvinyl alcohol, and methylcellulose; Preferably, the concentration of the polymer material-4 is 0.04 g / mL to 1 g / mL; Preferably, the concentration of surfactant-3 is 1 μg / mL-20 μg / mL; Preferably, surfactant-3 is selected from nonionic surfactants; Preferably, the active factor-3 is an active factor that can induce fibroblast adhesion and regeneration; Preferably, the concentration of the active factor-3 is 25-1000 ng / mL; Preferably, the solvent-4 is selected from one, two or more of hexafluoroisopropanol, cresol, chloroform, formic acid, N,N-dimethylformamide, N,N-dimethylacetamide, trifluoroacetic acid, acetone, tetrahydrofuran, dimethyl sulfoxide, trifluoroethanol, dichloromethane, saturated zinc chloride solution, saturated calcium chloride solution, ethanol, methanol and acetic acid.
9. A gradient bionic scaffold prepared by the preparation method according to any one of claims 2 to 8.
10. Use of the preparation method according to any one of claims 2 to 8 and the gradient bionic scaffold according to any one of claims 1 to 2 and 9 in oral tissue engineering.
Citation Information
Patent Citations
Bone repair film and preparation method thereof
CN109876192A
Gradient material for guiding regeneration of periodontal hard and soft tissues and preparation method of gradient material
CN110141687A
Soft and hard tissue integrated regeneration-repair gradient three-dimensional fibrous scaffold and preparation method thereof
CN110772668A
Thermoplastic material / soft tissue symbiotic bone implant based on 3D printing
CN111297518A
Oral cavity repairing film for alveolar bone regeneration and preparation method of oral cavity repairing film
CN116269868A
